Eleven Biotherapeutics Presents Data on Ocular Therapeutics Pipeline at the ARVO 2015 Annual Meeting

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, has announced the presentation of data for EBI-031, its novel, protein therapeutic IL-6 inhibitor in preclinical development for diabetic macular edema (DME), at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting. These preclinical pharmacokinetic studies with EBI-031, which have been optimized for intravitreal administration using Eleven’s AMP-Rx technology, confirmed the ability of EBI-031 to potently inhibit IL-6 signaling with extended vitreal retention compared to existing therapies. The Company plans to file an investigational new drug (IND) application with FDA by the end of 2015 for clinical development of EBI-031 in DME.

“We are very encouraged by this preclinical pharmacokinetic data demonstrating that we have successfully achieved the important design criteria necessary for an intravitreal IL-6 antagonist and supporting our development plans for EBI-031 in diabetic macular edema,” said Abbie Celniker, President and CEO of Eleven Biotherapeutics. “Based on these data, including potent inhibition of IL-6 signaling, extended vitreal retention compared to existing therapies and rapid systemic clearance, we plan to file an IND application with the FDA by the end of 2015 for clinical development of EBI-031 in DME.”

In a poster presentation entitled, “Optimized Intravitreal IL-6 Antagonist for the Treatment of Diabetic Macular Edema”, Eleven Biotherapeutics researchersdescribe the preclinical data demonstrating that EBI-031 has successfully achieved key design criteria and optimized drug-like properties necessary for an intravitreal IL-6 antagonist including potent blockade of IL-6 signaling, and pharmacokinetics properties such as extended vitreal retention and rapid systemic clearance. Highlights of the poster include

•       Potent blockade of both bound (IL-6/sIL-6Rα complex trans-signaling) and free IL-6 (cis-signaling)

o   EBI-031 blocks free IL-6 (cis-signaling) >900 fold more potently than standard of care tocilizumab and unlike tocilizumab, potently inhibits hyper IL-6, a genetic fusion of the IL-6/sIL-6Rα trans-signaling complex

•       Slow vitreal clearance compared to existing therapies to support monthly or greater frequency of dosing

o   EBI-031 cleared in approximately 10 days compared to aflibercept at approximately 6 days and tocilizumab at approximately 5 days in pharmacokinetic studies performed in New Zealand white rabbits injected IVT bilaterally

•       Rapid systemic clearance and low systemic accumulation of molecules that escape the eye to minimize toxicity

o   Following IV administration in rabbits, EBI-031 is cleared from systemic circulation approximately two times faster than aflibercept, or tocilizumab, and demonstrated lower systemic accumulation than these agents

•       Extended duration of EBI-031 blockade through predictive modeling

o   Due to its high potency and long vitreal retention, EBI-031 is predicted to inhibit 95% of IL-6 signaling for >100 days following a single 50 mg/mL IVT injection in humans compared to 10 days for tocilizumab or 60 days for aflibercept

•       Efficient penetration of ocular tissues

o   EBI-031 molecule detected at high levels in the aqueous, choroid, and retina following IVT administration.